NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why Micropolis Holding Co. (NYSE American: MCRP) Is ‘One to Watch’
Micropolis (NYSE American: MCRP) is a robotics and AI technology company pioneering the development of unmanned…
-
QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Positioned in North America’s Critical Minerals Future
Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) was featured in a recent article that discusses the…
-
QualityStocksNewsBreaks – Copper’s Moment: Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Taps Rising Demand with BC Projects and Custom Mill
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF), a junior exploration and custom milling company, is poised…